A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With FGFR Genomic Alterations
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Erdafitinib (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 10 Jun 2017 Biomarkers information updated
- 07 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 24 Aug 2018.
- 20 Feb 2017 Planned End Date changed from 1 Jul 2018 to 1 Nov 2018.